Novartis Announces Positive Six-Year Overall Survival Data for Kisqali in Early Breast Cancer

Novartis reported positive six-year follow-up results from the Phase III NATALEE trial for Kisqali (ribociclib) in early breast cancer patients, demonstrating a 20% reduction in the risk of death compared to endocrine therapy alone. The invasive disease-free survival benefit increased from 4.1% at five years to 5.3% at six years, and breast cancer-specific deaths were reduced by 30%. These results highlight the long-term clinical value of Kisqali, with benefits persisting after therapy completion.